1-(Pyridazin-3-yl)pyrrolidin-3-amine dihydrochloride

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-(Pyridazin-3-yl)pyrrolidin-3-amine dihydrochloride
• 英文别名: 1-pyridazin-3-ylpyrrolidin-3-amine;dihydrochloride
• 化学式: C8H14Cl2N4
• 分子量: 237.13
• InChiKey: RZZAQARYTUZOQI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.86
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  55
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• [EN] 1, 3, 4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER<br/>[FR] COMPOSÉS DE 1,3,4-THIADIAZOLE ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
  申请人：ASTRAZENECA AB

  公开号：WO2015181539A1

  公开（公告）日：2015-12-03

  The specification relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where Q, R, R1 and R2 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent GLS1 mediated disease, including cancer. The specification further relates to crystalline forms of compounds of Formula (I) and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating GLS1 kinase mediated disease, including cancer, using such compounds and salts.

  本规范涉及到式（I）的化合物及其药用盐，其中Q、R、R1和R2具有本文中定义的任何含义。本规范还涉及使用这些化合物和其盐治疗或预防GLS1介导的疾病，包括癌症。本规范还涉及到式（I）的化合物的晶型形式及其药用盐；包含这些化合物和盐的药物组合物；包括这些化合物和盐的试剂盒；制造这些化合物和盐的方法；在制造这些化合物和盐中有用的中间体；以及使用这些化合物和盐治疗GLS1激酶介导的疾病，包括癌症的方法。
• 1, 3, 4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER
  申请人：Astrazeneca AB

  公开号：EP3148994A1

  公开（公告）日：2017-04-05